linjc16/ctgov huggingface dataset:
ED Hypernatremia. Prognostic Factors and Epidemiology.

Study Overview
=================
Brief Summary
-----------------
This study evaluate the 1-month mortality of patients who proceed a blood sample while in the ED with an hypernatremia (>145 mmol/l). This prospective study will try to show several prognostic factors, and show the epidemiology of hypernatremia in this single center evaluation.

Official Title
-----------------
Emergency Departement (ED) Hypernatremia. Prognostic Factors and Epidemiology. About a Single-center Prospective Study

Conditions
-----------------
Hypernatremia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Natremia > 145 mmol/l Exclusion Criteria: Age < 18 years Refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| one month survival | Survival at 1 month after the blood sample at the ED | 1 month |
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.

Official Title
-----------------
A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis

Conditions
-----------------
Secondary Hyperparathyroidism, End Stage Renal Disease

Intervention / Treatment
-----------------
* Drug: AMG 073
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients must be receiving hemodialysis; * Have elevated parathyroid hormone levels; * Not be pregnant or nursing; and * Not have had a heart attack in the last 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AMG 073<br> | Drug: AMG 073<br>* 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally<br>|
| Placebo Comparator: placebo<br> | Drug: Placebo<br>* 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase. |  | efficacy assessment phase (last 14 weeks of treatment) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of AMG 073 compared with placebo by determining: percentage change from baseline in mean calcium x phosphorus product (Ca x P) during the efficacy assessment phase |  | efficacy assessment phase (last 14 weeks of treatment) | 
| To evaluate the efficacy of AMG 073 compared with placebo by determining: changes in self-reported cognitive function from baseline to the end of the efficacy assessment phase |  | efficacy assessment phase (last 14 weeks of treatment) | 
| To evaluate the safety of AMG 073 compared with placebo. |  | entire study |
Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to propose new treatment algorithm (strategy) for patients with Acute Coronary Syndrome (ACS) and left bundle-branch block (LBBB).

Detailed Description
-----------------
Current recommendations on the treatment of acute coronary syndrome (ACS) dictate urgent reperfusion therapy in the case of evolving myocardial infarction with ST-segment elevation (STEMI). Optimal use of PCI (preferably) or thrombolysis in this situation requires a rapid and correct diagnosis. According to the ESC'2008 and ACC/AHA'2009 focused update guidelines patients admitted to the hospital within 12 hours after the onset of chest pain with new (or presumably new) left bundle-branch block (LBBB) should be treated like patients having STEMI (class I, level A). However, it is well-known that in patients with concomitant LBBB, the ECG manifestations of acute myocardial injury may be masked. ACS may occur in a patient with true old LBBB (when doctor has/has not an ability to compare the new ECG with the previous one) or (presumably) new LBBB. There is a high risk of non receiving appropriate therapy or of receiving inappropriate therapy (thrombolysis instead of LMWH/UFH/fondaparinux).

Conditions
-----------------
Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Procedure: PCI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 75 years Ischemic discomfort (ie, ischemic chest pain or equivalent) at rest ≥20 minutes within previous 24 hours. Any (new, presumably new, or old) LBBB on the prehospital (ambulance) or admission ECG. Urgent coronary angiography (followed, when indicated, by PCI), ideally within 90 minutes after admission Exclusion Criteria: all-comers design

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: PCI|urgent PCI on admission|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants survived |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute coronary syndrome, percutaneous coronary intervention, left bundle branch block
Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents

Study Overview
=================
Brief Summary
-----------------
Background: Biofeedback and medical treatments have been extensively used for moderate fecal incontinence. There is limited data comparing and combining these two treatments. Aim: To evaluate the effect of biofeedback and medical treatments, separately and in combination. Methods: Sixty-five consecutive female patients, referred to a tertial center for fecal incontinence were included. The patients were randomized to start with either biofeedback (4-6 months) or medical treatment with loperamide and stool-bulking agents (2 months). Both groups continued with a combination treatments, i.e. medical treatment was added to biofeedback and vice versa. A two-week prospective bowel symptom diary and anorectal physiology were evaluated at baseline, after single- and combination treatments.

Official Title
-----------------
Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents is Effective for the Treatment of Fecal Incontinence in Women - a Randomized Controlled Trial

Conditions
-----------------
Fecal Incontinence

Intervention / Treatment
-----------------
* Behavioral: Biofeedback
* Drug: Loperamide
* Drug: Stool bulking agent (stericulia or isphagula husk)
* Other: Combination of biofeedback and medical treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years of age Patients with at least one or more episodes of FI during a period of 2 weeks as recorded by bowel function diary Patients from whom written consent was obtained Exclusion Criteria: Previous congenital or acquired spinal injury, spinal tumour or spinal surgery Presence of neurological diseases or peripheral vascular disease Uncontrolled diabetes mellitus Congenital anorectal malformations Recent colorectal or gastrointestinal surgery Presence of external full-thickness rectal prolapse Inflammatory bowel disease Chronic diarrhoea Use of tibial nerve or sacral nerve stimulations Ongoing pregnancy Any malignant disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biofeedback<br> | Behavioral: Biofeedback<br> <br> |
| Experimental: medical treatment<br> | Drug: Loperamide<br> <br> Drug: Stool bulking agent (stericulia or isphagula husk)<br> <br> |
| Experimental: combination of the two treatments<br> | Other: Combination of biofeedback and medical treatment<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| symptom diary |  | Up to eight months |
Probiotics for Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
This randomised, double blind, cross-over study compares the effect (symptoms, fecal bacterial growth, gas production) of three weeks' treatment with lactobacillus plantarum MF 1298 with placebo in patients with irritable bowel syndrome. The results are related to dietary habits, food intolerance and food allergy.

Official Title
-----------------
Lactobacillus Plantarum MF 1298 vs Placebo for Irritable Bowel Syndrome.

Conditions
-----------------
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: placebo followed by Lactobacillus plantarum MF 1298
* Dietary Supplement: Lactobacillus plantarum MF1298 followed by placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Irritable bowel syndrome according to the Rome II criteria regular symptoms Exclusion Criteria: Use of probiotics last three weeks pregnancy lactation co-existing other gastrointestinal disorders use of laxatives and antibiotics within last 5 weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: placebo followed by probiotic<br>placebo, then washout period, then Lactobacillus plantarum MF1298 | Dietary Supplement: placebo followed by Lactobacillus plantarum MF 1298<br>* placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks<br>* Other names: probiotic;|
| Experimental: probiotic followed by placebo<br>Lactobacillus plantarum MF1298, then washout period, then placebo | Dietary Supplement: Lactobacillus plantarum MF1298 followed by placebo<br>* Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks<br>* Other names: probiotic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfactory relief of abdominal symptoms | relief of symptoms recorded on diary cards | 11 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graded measurement of abdominal symptoms | IBS sum score | 11 weeks | 
| Fecal bacterial count |  | 11 weeks | 
| Abdominal gas |  | 11 weeks | 
| Immunological parameters |  | 11 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Probiotics
Thick vs. Thin Acellular Dermal Matrix (ADM)

Study Overview
=================
Brief Summary
-----------------
To study and compare a thick vs thin acellular dermal matrix for root coverage using the coronally positioned tunnel technique.

Official Title
-----------------
Root Coverage Using the Coronally Positioned Tunnel Technique Comparing Thick Versus Thin Acellular Dermal Matrix

Conditions
-----------------
Gingival Recession

Intervention / Treatment
-----------------
* Procedure: Thin ADM
* Procedure: Thick ADM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A. At least one Miller Class I or II mucogingival defect ≥ 3 mm (Miller 1985). B. The mucogingival defect must be on a non-molar tooth. C. Patients must be ≥ 18 years of age. Exclusion Criteria: A. Patients with debilitating systemic or diseases that significantly affect the periodontium. B. Patients with a known allergy to any of the materials that will be used in the study, including systemic antibiotics (tetracycline and doxycycline). C. Patients requiring antibiotic prophylaxis. D. Root surface restorations at the site of recession. E. No detectable CEJ F. Patients who fail to maintain acceptable oral hygiene levels at the test and adjacent teeth. G. Patients who are pregnant or lactating. H. Patients who use tobacco products (smoking or smokeless tobacco). I. Patients with alcohol abuse problems. J. Patients undergoing long-term steroid therapy. K. History of previous root coverage procedures, graft or GTR, on the test teeth. L. Patients who fail to complete the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Thin ADM<br>Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR) | Procedure: Thin ADM<br>* Use of soft tissue allograft for root coverage<br>* Other names: Thin acellular dermal matrix (ADM GBR);|
| Active Comparator: Thick ADM<br>Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM) | Procedure: Thick ADM<br>* Periodontal surgical procedure to coronally position the tissue over the ADM allograft<br>* Other names: Thick acellular dermal matrix graft (ADM);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent root coverage | Between 0 and 100% | Six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Creeping Attachment | Amount in millimeters | Six months |
The Study of Genes Localization for Female Pelvic Floor Dysfunction

Study Overview
=================
Brief Summary
-----------------
Female pelvic floor dysfunction (FPD) is due to defects in the pelvic support structures, degradation, damage or dysfunction. The main problem of which is pelvic organ prolapse(POP), urinary incontinence(UI) and genital tract injury. Although it does not pose a serious threat to life, but affect the patient's quality of life seriously in the physical, psychological, social behavior and other aspects. With the growing aging population, the incidence rate has gradually increased, and increasing demands for people's quality of life simultaneously, more and more attention was raised to PFD as common chronic diseases. In recent years, the basic research, epidemiology, prevention, diagnosis and treatment of PFD have made great progress, especially in developing gynecological urology theory and reconstructive pelvic surgery. But overall the basic research of PFD is lagging behind, especially susceptibility gene localization and functional studies did not get enough attention.

Official Title
-----------------
The Study of Susceptibility Genes Localization for Female Pelvic Floor Dysfunction

Conditions
-----------------
Female Pelvic Floor Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female aging from 30 to 70-year old; preoperative diagnosis of gynecologic malignancies; have the ability to comply with Research programs; voluntarily participate in the study and signed an informed consent form Exclusion Criteria: patients with severe cardiovascular diseases, kidney, liver and other vital organs diseases, bone marrow disease and mental illness; patients suffering from autoimmune diseases; patients with acute infectious disease or infection early phase of infection; patients with urinary tract infection; patients with infection or erosion of ano-genital skin; for any other reason, the researchers considered unsuitable for inclusion.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experiment group<br>patients with FPFD | |
| control group<br>patients without FPFD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| susceptibility genes localization | Based on high-throughput sequencing platform, we expect to screen out susceptibility genes location in PFD, providing theoretical basis for individualized prevention, intervention and treatment. | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
female pelvic floor dysfunction, pelvic organ prolaps, urinary incontinence, massively parallel sequencing
Magnetocardiography Endocrine Registry

Study Overview
=================
Brief Summary
-----------------
Endocrine disorders like Type 2 diabetes mellitus (T2DM) represent complex cardiometabolic disease processes affecting approximately 462 million individuals worldwide and is associated with a two- to three-fold increase in cardiovascular mortality. Individuals with T2DM are at an increased risk of developing cardiovascular disease. Research has shown individuals with T2DM and no previous history of coronary artery disease are still at similar risk rates for cardiovascular events as patients with a prior myocardial infarction. The MAgenetoCardiography ENDOcrine Registry (MACENDOR) study is designed to collect CardioFlux scans on a select group of volunteers who are high-risk patients with endocrine disorders. CardioFlux is used as a noninvasive magnetocardiography (MCG) tool that analyzes and records the magnetic fields of the heart to screen volunteers for heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 250 volunteers who present to the Genetesis facility for a 5-minute CardioFlux scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.

Official Title
-----------------
Magnetocardiography Endocrine Registry

Conditions
-----------------
Endocrine Disorder

Intervention / Treatment
-----------------
* Diagnostic Test: CardioFlux


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years of age at the time of enrollment Patients deemed at risk for cardiovascular disease from endocrine disorders Exclusion Criteria: < 18 years of age Patients unable to fit into device Non-ambulatory patients Positive response(s) on CardioFlux Pre-Screening Form Patients with claustrophobia or unable to lie supine for five minutes Pregnant women Poor candidates for follow-up (e.g., no access to phone) Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CardioFlux|Magnetocardiography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy statistics | analyzing the accuracy of CardioFlux | 12 months | 
| Specificity statistics | analyzing the specificity of CardiFlux | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MCG, endocrine disorders, Cardiovascular disease, ischemia, CardioFlux